Oritinib

A tyrosine kinase inhibitor used in cancer treatment

Oritinib is a tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain types of cancer. It functions by inhibiting the activity of specific enzymes known as tyrosine kinases, which play a crucial role in the signaling pathways that regulate cell division and survival. By blocking these enzymes, oritinib can help to slow down or stop the growth of cancer cells.

Mechanism of Action

Oritinib targets the epidermal growth factor receptor (EGFR), a protein that is often overexpressed or mutated in various cancers. EGFR is a receptor tyrosine kinase that, when activated, triggers a cascade of downstream signaling pathways that promote cell proliferation and survival. Oritinib binds to the ATP-binding site of the EGFR, preventing its activation and subsequent signaling. This inhibition can lead to reduced tumor growth and increased cancer cell death.

Clinical Use

Oritinib is used in the treatment of non-small cell lung cancer (NSCLC) and other cancers that exhibit overexpression or mutations in the EGFR. It is particularly effective in patients whose tumors have specific mutations in the EGFR gene, which make them more susceptible to TKI therapy.

Side Effects

Common side effects of oritinib include skin rash, diarrhea, and fatigue. These side effects are generally manageable with supportive care and dose adjustments. More serious side effects can include interstitial lung disease and liver toxicity, which require careful monitoring and management by healthcare professionals.

Development and Approval

Oritinib was developed as part of a class of targeted cancer therapies designed to interfere with specific molecular targets involved in tumor growth and progression. Its development involved extensive preclinical and clinical testing to establish its efficacy and safety profile.

Related Pages

• Tyrosine kinase inhibitor
• Epidermal growth factor receptor
• Non-small cell lung cancer
• Cancer treatment

Chemical structure of oritinib